1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Imaging in gynecological disease (27) : clinical and ultrasound characteristics of recurrent ovarian stromal cell tumors
(
- Contribution to journal › Article
- 2023
-
Mark
Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors : retrospective validation on IOTA 5 multicenter cohort
(
- Contribution to journal › Article
- 2022
-
Mark
Imaging in gynecological disease (23) : clinical and ultrasound characteristics of ovarian carcinosarcoma
(
- Contribution to journal › Article
- 2021
-
Mark
Imaging in gynecological disease (22) : clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors
(
- Contribution to journal › Article
-
Mark
Terms, definitions and measurements to describe sonographic features of lymph nodes : consensus opinion from the Vulvar International Tumor Analysis (VITA) group
(
- Contribution to journal › Article
-
Mark
Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement : ABRAX international retrospective cohort study
(
- Contribution to journal › Article
- 2020
-
Mark
Imaging in gynecological disease (20) : clinical and ultrasound characteristics of adnexal torsion
(
- Contribution to journal › Article
- 2018
-
Mark
Imaging in gynecological disease (14) : clinical and ultrasound characteristics of ovarian clear cell carcinoma
(
- Contribution to journal › Article
-
Mark
Imaging in gynecological disease (13) : clinical and ultrasound characteristics of endometrioid ovarian cancer
2018) In Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 52(4). p.535-543(
- Contribution to journal › Article
-
Mark
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
(
- Contribution to journal › Article